VIDEO: Exciting movement happening in KRAS-mutated lung cancer treatments
In this video, Pasi Jänne, MD, PhD, professor of medicine, Harvard Medical School, discussed studies looking at combining therapies with sotorasib. Those combinations included sotorasib and trametinib for KRAS p.G12C-mutated solid tumors and sotorasib and afatinib for KRAS p.G12C mutated non-small cell lung cancer.
Although the combinations showed activity, it did not appear to be better than the single agent activity of sotorasib, Jänne said.
"It is interesting for the field to ponder why that is not the case. We have a lot of preclinical hypotheses and experiments to suggest that some of these combination therapies are effective or more effective than single agents, but we did not really see that here," Jänne said.
The findings contrast with two presentations at ESMO in colon cancer, which showed greater activity with combinations compared with single agent sotorasib, Jänne said. "The exciting part is there is definitely movement in new therapies in KRAS space."
Collapse
Gandara D, et al. A phase 1b study evaluating the combination of sotorasib, a KRAS G12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC).Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10 2021.
Ramalingam S, et al. A phase 1b study evaluating the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-mutated solid tumors. Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10 2021.